Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GCK | P35557 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | METAP1 | P53582 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SCD | O00767 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.49 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664647 | 0.83 | GCK (0.49) | RAB9ANPC1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2664665 | 0.81 | GCK (0.49) | RAB9ANPC1MEN1KMT2ALMNA | |
| SCHEMBL2664687 | 0.81 | GCK (0.47) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL19879550 | 0.81 | ALOX15 (0.67) | RAB9ANPC1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2664719 | 0.81 | RAB9A (0.51) | RAB9ANPC1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2664657 | 0.81 | SMN1; SMN2 (0.54) | RAB9ANPC1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2664720 | 0.80 | GCK (0.53) | RAB9ANPC1SMN1; SMN2HPGDMEN1 | |
| SCHEMBL2664750 | 0.80 | GCK (0.65) | RAB9ANPC1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL2664655 | 0.80 | GCK (0.52) | RAB9ANPC1MEN1KMT2ALMNA | |
| SCHEMBL1796180 | 0.80 | CSNK2A2 (0.55) | RAB9ANPC1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| EP-1987831-A1 | COMPOUNDS EFFECTING GLUCOKINASE | AstraZeneca AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| EP-1695705-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-08-30 | — | — | EP | disclosed |
| EP-1669069-A1 | Compounds effecting glukokinase | AstraZeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| EP-1661569-A1 | Compounds effecting glucokinase | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | RAB9A 3175/4885NPC1 1139/4885SMN1; SMN2 1886/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | RAB9A 3175/4885NPC1 1139/4885SMN1; SMN2 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.